KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Shares Issued (2016 - 2025)

Neogenomics' Shares Issued history spans 16 years, with the latest figure at $431000.0 for Q4 2025.

  • For Q4 2025, Shares Issued fell 37.26% year-over-year to $431000.0; the TTM value through Dec 2025 reached $962000.0, down 79.29%, while the annual FY2025 figure was $962000.0, 79.29% down from the prior year.
  • Shares Issued reached $431000.0 in Q4 2025 per NEO's latest filing, down from $765000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $6.4 million in Q1 2022 to a low of -$1.2 million in Q2 2025.
  • Average Shares Issued over 5 years is $1.9 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Shares Issued: soared 2013.98% in 2024, then plummeted 160.17% in 2025.
  • A 5-year view of Shares Issued shows it stood at $3.0 million in 2021, then tumbled by 37.58% to $1.9 million in 2022, then crashed by 31.28% to $1.3 million in 2023, then plummeted by 46.08% to $687000.0 in 2024, then plummeted by 37.26% to $431000.0 in 2025.
  • Per Business Quant, the three most recent readings for NEO's Shares Issued are $431000.0 (Q4 2025), $765000.0 (Q3 2025), and -$1.2 million (Q2 2025).